Tristel PLC Tristel's Duo for Ultrasound approved in India
August 21 2020 - 1:00AM
RNS Non-Regulatory
TIDMTSTL
Tristel PLC
21 August 2020
Tristel plc
("Tristel" or the "Company")
Tristel's Duo for Ultrasound approved in India
Tristel plc (AIM: TSTL), the manufacturer of infection
prevention products, announces that its Duo high-level
disinfectants, branded Duo ULT, Duo OPH and Duo EVE, have been
approved for the decontamination of semi-critical medical devices
by India's Medical Device & Diagnostics Division, Central Drugs
Standard Control Organisation (CDSCO).
Duo ULT is intended for use on invasive ultrasound probes; Duo
OPH is intended for use on ophthalmic instruments; and Duo EVE is
intended for use on Mobile ODT's hand-held EVA colposcope and
associated instruments used in gynaecological procedures.
In 2019 the Company received regulatory approvals from the CDSCO
for Stella, which is an instrument soaking system for urological
instruments, and Rinse Assure which is used with endoscope
washer-disinfectors. Tristel incorporated Tristel India Private
Limited during its 2018 financial year.
Duo is a hand-held dispenser which applies the Company's
powerful chlorine dioxide chemistry as a foam to the surface of
medical devices. Tristel Duo is widely used throughout Europe, the
Middle East and the Asia-Pacific region and the Company is seeking
approval for Duo ULT from the United States Food and Drug
Administration. Worldwide sales of all Duo branded products for
medical device disinfection were GBP3.9m in the 2020 financial
year, an increase of 56% on the prior year.
Paul Swinney, CEO of Tristel commented: "Every regulatory
approval we achieve represents an important milestone in our
progress, and this Indian approval for the use of our high-level
disinfectants on invasive medical devices is no exception. The
three Duo products provide Indian hospitals with an affordable and
easy-to-use high-level disinfection method for medical devices used
in ultrasound, ophthalmology, and gynaecology. Infection prevention
experts within India acknowledge the need for disinfection
technologies that will enable hospitals to raise their
decontamination standards. Combining these latest approvals with
those previously gained gives us a broad product offering for the
Indian market.
"We can now press on with developing our commercial plan for
India. We have initiated discussions with various potential
partners for distribution of the products."
For further information please contact:
Tristel plc Tel: 01638 721 500
Paul Swinney, Chief Executive
Officer
Liz Dixon, Finance Director
Walbrook PR Ltd Tel: 020 7933 8780 or tristel@walbrookpr.com
Paul McManus Mob: 07980 541 893
Lianne Cawthorne Mob: 07584 391 303
finnCap Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate
Finance)
Alice Lane (ECM)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAKZGZRFGRGGZM
(END) Dow Jones Newswires
August 21, 2020 02:00 ET (06:00 GMT)
Tristel (LSE:TSTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tristel (LSE:TSTL)
Historical Stock Chart
From Apr 2023 to Apr 2024